Ariad Pharma (ARIA) Misses Q1 Loss Views by 3c

Ariad Pharma (NASDAQ: ARIA) reported Q1 EPS of ($0.29), $0.03 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $81 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Ariad Pharma (ARIA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c
• Alabama Power Co. 5.875% Sr. Notes Series 2007b (ALM) Tops Q2 EPS by 62c